Cost-effectiveness analysis of dinutuximab β for the treatment of high-risk neuroblastoma in China.

An-Le Shen Yi-Jin GaoLi-Ting YuAn-An ZhangBin WuYe FangYa-Li HanChen-Sui-Zi LiZhi-Ling LiYi-Jin GaoShun-Guo Zhang

Published in: Pediatric blood & cancer (2023)

Results found that dinutuximab β is not a cost-effective treatment option for children with high-risk NB unless its price is significantly reduced.

Keyphrases